Feedback PLC Director Appointment (9144T)
30 November 2021 - 12:35AM
UK Regulatory
TIDMFDBK
RNS Number : 9144T
Feedback PLC
29 November 2021
Feedback plc
Appointment of Anesh Patel as Chief Financial Officer and
Company Secretary
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the
specialist clinical communication company, is pleased to announce
that further to previous announcements, Anesh Patel has been
appointed to the board of directors as Chief Financial Officer and
Company Secretary with immediate effect.
Anesh Patel was appointed as Chief Financial Officer of
Feedback's wholly owned subsidiary, Feedback Medical Limited, in
May 2021 as part of a succession planning programme following
Lindsay Melvin's (Chief Financial Officer and Company Secretary of
Feedback) decision to retire from the board of Feedback during H2
2021. Anesh has worked alongside Lindsay over the past months to
ensure a smooth and orderly transition.
Anesh joined Feedback Medical Limited from hVIVO Limited, a
subsidiary of AIM-listed Open Orphan plc and a rapidly growing,
industry-leading, clinical services provider to pharma, biotech and
government organisations where most recently he was finance &
corporate projects director. Prior to hVIVO, he spent seven years
in investment banking where he specialised in corporate finance
advisory services, at leading banks including Société Générale and
Standard Bank. Anesh started his professional career with Ernst
& Young in 2004 where he qualified as a chartered accountant,
initially working within the audit & assurance division before
transferring to the transaction support team for private equity
clients. He graduated from University College London (UCL) and
holds an M.Sci. (Hons) degree in Mathematics with Economics.
Rory Shaw, Chairman of Feedback, commented: "We welcome Anesh to
the Board of Feedback. He joined the team earlier this year and has
already proven the value he brings through his contribution to the
successful GBP11.2 million fundraise recently announced. His broad
financial and commercial experience provides a good balance to the
medical and technical expertise we have across the Board, creating
a strong team to take the Company forward. I would also like to
take this opportunity to thank Lindsay for his work guiding the
Company through its formative years, and for enabling a smooth
handover to ensure Feedback continues on this trajectory of growth.
We believe that Feedback is set for a bright and exciting future
ahead."
Aneshkumar (Anesh) Ishwarbhai Patel (aged 40) does not currently
hold any directorships and has no previous directorships (within 5
years). Anesh Patel has confirmed that there is no further
information to be disclosed pursuant to paragraph (g) of Schedule 2
of the AIM Rules.
Enquiries:
Feedback plc +44 (0)1954 718072
Tom Oakley, CEO IR@fbk.com
Anesh Patel, CFO
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Emma Earl/Freddy Crossley (Corporate
Finance)
Rupert Dearden (Corporate Broking) +44 (0)20 7886 2500
Walbrook PR Ltd Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Paul McManus/Nick Rome/Nicholas Johnson 07980 541 893 or 07748 325 236
or 07884 664 686
Notes to Editors
Feedback plc (AIM: FDBK) is a pioneer of regulated clinical
communication products. Its core product, Bleepa, is a
revolutionary medical imaging communications app, providing an
easy-to-use, high quality tool to enable remote and secure
communications between front-line clinicians and teams.
Importantly, it is the only CE marked medical imaging
communications platform on the NHSx clinical communications tools
framework. Bleepa has unparalleled functionality for everyday
practice and can be accessed from any internet-connected device,
enabling control of patient cases when on the go.
Its highly scalable Software as a Service ("SaaS") based revenue
model will provide increasing levels of visibility as the Company
grows its customer base. With a growing distribution base and
technology in place, the focus is on leveraging key relationships
in order to drive sales both in the UK and internationally to all
forms of care providers. As a fully certified medical device,
Bleepa aims to disrupt the medical imaging communications market
and, importantly, increase the accuracy and speed of clinical
review.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOADKCBBNBDDFDB
(END) Dow Jones Newswires
November 29, 2021 08:35 ET (13:35 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Apr 2024 to May 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From May 2023 to May 2024